SG11201610341PA - Phosphatidylinositol 3-kinase inhibitors - Google Patents
Phosphatidylinositol 3-kinase inhibitorsInfo
- Publication number
- SG11201610341PA SG11201610341PA SG11201610341PA SG11201610341PA SG11201610341PA SG 11201610341P A SG11201610341P A SG 11201610341PA SG 11201610341P A SG11201610341P A SG 11201610341PA SG 11201610341P A SG11201610341P A SG 11201610341PA SG 11201610341P A SG11201610341P A SG 11201610341PA
- Authority
- SG
- Singapore
- Prior art keywords
- phosphatidylinositol
- kinase inhibitors
- kinase
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462016194P | 2014-06-24 | 2014-06-24 | |
PCT/US2015/037234 WO2015200352A1 (en) | 2014-06-24 | 2015-06-23 | Phosphatidylinositol 3-kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201610341PA true SG11201610341PA (en) | 2017-01-27 |
Family
ID=53674285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201610341PA SG11201610341PA (en) | 2014-06-24 | 2015-06-23 | Phosphatidylinositol 3-kinase inhibitors |
Country Status (19)
Country | Link |
---|---|
US (2) | US9765060B2 (en) |
EP (1) | EP3160960B1 (en) |
JP (2) | JP6391718B2 (en) |
KR (1) | KR20170015521A (en) |
CN (1) | CN106459008A (en) |
AR (1) | AR100975A1 (en) |
AU (1) | AU2015280138B2 (en) |
BR (1) | BR112016029846A2 (en) |
CA (1) | CA2953820A1 (en) |
EA (1) | EA201692487A1 (en) |
ES (1) | ES2900812T3 (en) |
HK (1) | HK1231474A1 (en) |
IL (1) | IL249404A0 (en) |
MA (1) | MA40045A (en) |
MX (1) | MX2016017110A (en) |
NZ (1) | NZ727185A (en) |
SG (1) | SG11201610341PA (en) |
TW (1) | TW201625558A (en) |
WO (1) | WO2015200352A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140213630A1 (en) | 2011-03-08 | 2014-07-31 | Thomas Diacovo | Methods and pharmaceutical compositions for treating lymphoid malignancy |
EP3154969B1 (en) | 2014-06-13 | 2019-10-09 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
EP3154958B1 (en) | 2014-06-13 | 2020-10-07 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
BR112016028642A2 (en) | 2014-06-13 | 2017-08-22 | Gilead Sciences Inc | compound, pharmaceutical composition, method of treating a disease or condition, method of inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide, method of inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, and, use of a compound, salt, isomer or a pharmaceutically acceptable mixture thereof. |
KR20170015508A (en) | 2014-06-13 | 2017-02-08 | 길리애드 사이언시즈, 인코포레이티드 | Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors |
CU24428B1 (en) | 2014-07-04 | 2019-06-04 | Lupin Ltd | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
TW201813963A (en) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
TW201815787A (en) * | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
TW201825465A (en) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
CN106632077B (en) * | 2016-10-10 | 2019-01-22 | 上海再启生物技术有限公司 | A kind of preparation method of 2- amino -4- Bromopyrimidine |
US10396145B2 (en) * | 2017-01-12 | 2019-08-27 | Micron Technology, Inc. | Memory cells comprising ferroelectric material and including current leakage paths having different total resistances |
WO2018237007A1 (en) * | 2017-06-22 | 2018-12-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of phosphoinositide 3-kinase and histone deacetylase for treatment of cancer |
AU2018309739B2 (en) * | 2017-07-31 | 2022-01-27 | The Trustees Of Columbia University In The City Of New York | Compounds, Compositions, and Methods for Treating T-cell Acute Lymphoblastic Leukemia |
AU2019209960B2 (en) | 2018-01-20 | 2023-11-23 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
EP3858830B1 (en) * | 2018-09-27 | 2022-11-16 | Shanghai Yingli Pharmaceutical Co. Ltd. | Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof |
CN110590681B (en) * | 2019-09-30 | 2021-06-01 | 中山大学 | Novel quinazoline ketone compound and preparation method and application thereof |
AR120324A1 (en) * | 2019-10-29 | 2022-02-09 | Biogen Ma Inc | SPIROCYCLIC O-GLUCOPROTEIN-2-ACETAMIDO-2-DEOXI-3-D-GLUCOPYRANOSIDASE INHIBITORS |
CN113512042A (en) * | 2020-04-09 | 2021-10-19 | 成都赜灵生物医药科技有限公司 | Substituted quinazoline-4-ketone compound and preparation method and application thereof |
WO2024064024A1 (en) * | 2022-09-19 | 2024-03-28 | Onkure, Inc. | ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives as p13k inhibitors for the treatment of cancer |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60144277D1 (en) | 2000-04-25 | 2011-05-05 | Icos Corp | HEMMER OF HUMAN PHOSPHATIDYL-INOSITOL-3-KINASE DELTA |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US8193182B2 (en) * | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
WO2009088990A1 (en) * | 2008-01-04 | 2009-07-16 | Intellikine, Inc. | Certain chemical entities, compositions and methods |
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
AR091790A1 (en) * | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | DERIVATIVES OF ISOQUINOLIN-1-ONA AND ITS USES |
US9029384B2 (en) * | 2012-12-21 | 2015-05-12 | Gilead Calistoga, LLC. | Phosphatidylinositol 3-kinase inhibitors |
WO2014128612A1 (en) * | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
UY35675A (en) * | 2013-07-24 | 2015-02-27 | Novartis Ag | SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA |
WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
WO2015168079A1 (en) * | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
EP3154969B1 (en) * | 2014-06-13 | 2019-10-09 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
BR112016028642A2 (en) * | 2014-06-13 | 2017-08-22 | Gilead Sciences Inc | compound, pharmaceutical composition, method of treating a disease or condition, method of inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide, method of inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, and, use of a compound, salt, isomer or a pharmaceutically acceptable mixture thereof. |
-
2015
- 2015-06-23 AR ARP150102013A patent/AR100975A1/en unknown
- 2015-06-23 KR KR1020177001682A patent/KR20170015521A/en active IP Right Grant
- 2015-06-23 MX MX2016017110A patent/MX2016017110A/en unknown
- 2015-06-23 SG SG11201610341PA patent/SG11201610341PA/en unknown
- 2015-06-23 CN CN201580034671.2A patent/CN106459008A/en active Pending
- 2015-06-23 CA CA2953820A patent/CA2953820A1/en not_active Abandoned
- 2015-06-23 EA EA201692487A patent/EA201692487A1/en unknown
- 2015-06-23 BR BR112016029846A patent/BR112016029846A2/en not_active IP Right Cessation
- 2015-06-23 MA MA040045A patent/MA40045A/en unknown
- 2015-06-23 ES ES15739079T patent/ES2900812T3/en active Active
- 2015-06-23 JP JP2016574424A patent/JP6391718B2/en not_active Expired - Fee Related
- 2015-06-23 AU AU2015280138A patent/AU2015280138B2/en not_active Ceased
- 2015-06-23 NZ NZ727185A patent/NZ727185A/en not_active IP Right Cessation
- 2015-06-23 US US14/747,931 patent/US9765060B2/en active Active
- 2015-06-23 WO PCT/US2015/037234 patent/WO2015200352A1/en active Application Filing
- 2015-06-23 EP EP15739079.0A patent/EP3160960B1/en active Active
- 2015-06-24 TW TW104120373A patent/TW201625558A/en unknown
-
2016
- 2016-12-06 IL IL249404A patent/IL249404A0/en unknown
-
2017
- 2017-05-22 HK HK17105165.9A patent/HK1231474A1/en unknown
- 2017-08-17 US US15/680,045 patent/US20180065953A1/en not_active Abandoned
-
2018
- 2018-03-19 JP JP2018051249A patent/JP2018090644A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL249404A0 (en) | 2017-02-28 |
TW201625558A (en) | 2016-07-16 |
EP3160960A1 (en) | 2017-05-03 |
JP2018090644A (en) | 2018-06-14 |
JP6391718B2 (en) | 2018-09-19 |
WO2015200352A1 (en) | 2015-12-30 |
US20160024054A1 (en) | 2016-01-28 |
AU2015280138B2 (en) | 2018-06-14 |
EA201692487A1 (en) | 2017-06-30 |
KR20170015521A (en) | 2017-02-08 |
US9765060B2 (en) | 2017-09-19 |
BR112016029846A2 (en) | 2017-08-22 |
HK1231474A1 (en) | 2017-12-22 |
JP2017519021A (en) | 2017-07-13 |
NZ727185A (en) | 2018-04-27 |
AR100975A1 (en) | 2016-11-16 |
CN106459008A (en) | 2017-02-22 |
US20180065953A1 (en) | 2018-03-08 |
MX2016017110A (en) | 2017-05-01 |
ES2900812T3 (en) | 2022-03-18 |
CA2953820A1 (en) | 2015-12-30 |
EP3160960B1 (en) | 2021-10-13 |
MA40045A (en) | 2021-06-02 |
AU2015280138A1 (en) | 2016-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287113A (en) | Smyd inhibitors | |
HK1231474A1 (en) | Phosphatidylinositol 3-kinase inhibitors 3- | |
HK1231477A1 (en) | Phosphatidylinositol 3-kinase inhibitors 3- | |
HK1231476A1 (en) | Phosphatidylinositol 3-kinase inhibitors 3- | |
IL257880B (en) | Beta-lactamase inhibitors | |
HK1223911A1 (en) | Phosphatidylinositol 3-kinase inhibitors 3- | |
IL246902B (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
IL249079A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
IL246785A0 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
SG11201609540TA (en) | Phosphatidylinositol 3-kinase inhibitors | |
HUE042335T2 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
IL248789A0 (en) | Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors | |
HK1226398A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
EP3116503A4 (en) | Hptp-beta inhibitors | |
PL3134395T3 (en) | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | |
PT3134396T (en) | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors | |
GB201401005D0 (en) | Inhibitor | |
EP3180003A4 (en) | Pkc-epsilon inhibitors | |
GB201418154D0 (en) | Inhibitors | |
AU2014900536A0 (en) | Inhibitors | |
AU2014900535A0 (en) | Inhibitors |